AI BIO MED MI MindWalk Accelerating pharma R&D and innovation through technology partnerships Biopharmaceutical companies are increasingly turning to alliances & partnerships to drive external innovation. Having raised over $80…
BIO MED MI MindWalk A year in review: Advancing antibody discovery and beyond As we step into 2025, we’re reflecting on a year full of significant advancements, particularly in enhancing our SaaS platform. These…
BIO MED MI MindWalk Early in silico screening for antibody developability and immunogenicity Developability or immunogenicity issues can derail antibody development late in the process, resulting in potentially high cost, late-stage…
AI BIO MED MI MindWalk Generative AI in drug discovery Following a breakout year of rapid growth, generative AI has been widely, and justifiably, described as an undisputed game-changer for…
BIO MED ECO MI MindWalk Epitope binning explained: A powerful tool for antibody development Epitope-based screening approaches are playing a pivotal role in the development of modern antibody therapies for various diseases…
